Preoperative subclinical hyperthyroidism in patients with papillary thyroid carcinoma

Clinical and Experimental Otorhinolaryngology

Volumn 7, Issue 4, 2014, Pages 312-318

  Ahn, Dongbin ^a   Sohn, Jin Ho ^a   Jeon, Jae Han ^a   Park, Junesik ^b  

^a Kyungpook National University School of Medicine   (South Korea)

^b Catholic University of Daegu   (South Korea)

Author keywords

Hyperthyroidism; Papillary carcinoma; Thyroid; Thyrotropin

Indexed keywords

EID: 84911368197     PISSN: 19768710     EISSN: 20050720     Source Type: Journal    
DOI: 10.3342/ceo.2014.7.4.312     Document Type: Article

References (25)

1. Col NF, Surks MI, Daniels GH. Subclinical thyroid disease: clinical applications. JAMA. 2004 Jan; 291(2): 239-43.
2. Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA. 2004 Jan; 291(2): 228-38.
3. Vadiveloo T, Donnan PT, Cochrane L, Leese GP. The Thyroid Epidemiology, Audit, and Research Study (TEARS): morbidity in patients with endogenous subclinical hyperthyroidism. J Clin Endocrinol Metab. 2011 May; 96(5): 1344-51.
4. Kim SS, Lee BJ, Lee JC, Song SH, Kim BH, Son SM, et al. Preoperative serum thyroid stimulating hormone levels in well-differentiated thyroid carcinoma is a predictive factor for lateral lymph node metastasis as well as extrathyroidal extension in Korean patients: a single-center experience. Endocrine. 2011 Jun; 39(3): 259-65.
5. Fiore E, Rago T, Provenzale MA, Scutari M, Ugolini C, Basolo F, et al. Lower levels of TSH are associated with a lower risk of papillary thyroid cancer in patients with thyroid nodular disease: thyroid autonomy may play a protective role. Endocr Relat Cancer. 2009 Dec; 16(4): 1251-60.
6. Hercbergs AH, Ashur-Fabian O, Garfield D. Thyroid hormones and cancer: clinical studies of hypothyroidism in oncology. Curr Opin Endocrinol Diabetes Obes. 2010 Oct; 17(5): 432-6.
7. Lin HY, Sun M, Tang HY, Lin C, Luidens MK, Mousa SA, et al. L-Thyroxine vs. 3, 5, 3'-triiodo-L-thyronine and cell proliferation: activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Am J Physiol Cell Physiol. 2009 May; 296(5): C980-91.
8. Yalcin M, Dyskin E, Lansing L, Bharali DJ, Mousa SS, Bridoux A, et al. Tetraiodothyroacetic acid (tetrac) and nanoparticulate tetrac arrest growth of medullary carcinoma of the thyroid. J Clin Endocrinol Metab. 2010 Apr; 95(4): 1972-80.
9. Belfiore A, Garofalo MR, Giuffrida D, Runello F, Filetti S, Fiumara A, et al. Increased aggressiveness of thyroid cancer in patients with Graves' disease. J Clin Endocrinol Metab. 1990 Apr; 70(4): 830-5.
10. Pellegriti G, Belfiore A, Giuffrida D, Lupo L, Vigneri R. Outcome of differentiated thyroid cancer in Graves' patients. J Clin Endocrinol Metab. 1998 Aug; 83(8): 2805-9.
11. Kim EY, Kim WG, Kim WB, Kim TY, Kim JM, Ryu JS, et al. Coexistence of chronic lymphocytic thyroiditis is associated with lower recurrence rates in patients with papillary thyroid carcinoma. Clin Endocrinol (Oxf). 2009 Oct; 71(4): 581-6.
12. Ahn D, Heo SJ, Park JH, Kim JH, Sohn JH, Park JY, et al. Clinical relationship between Hashimoto's thyroiditis and papillary thyroid cancer. Acta Oncol. 2011 Nov; 50(8): 1228-34.
13. Sanders LE, Cady B. Differentiated thyroid cancer: reexamination of risk groups and outcome of treatment. Arch Surg. 1998 Apr; 133(4): 419-25.
14. Gerschpacher M, Gobl C, Anderwald C, Gessl A, Krebs M. Thyrotropin serum concentrations in patients with papillary thyroid microcancers. Thyroid. 2010 Apr; 20(4): 389-92.
15. Lin HY, Tang HY, Shih A, Keating T, Cao G, Davis PJ, et al. Thyroid hormone is a MAPK-dependent growth factor for thyroid cancer cells and is anti-apoptotic. Steroids. 2007 Feb; 72(2): 180-7.
16. Zafon C. TSH-suppressive treatment in differentiated thyroid cancer. A dogma under review. Endocrinol Nutr. 2012 Feb; 59(2): 125-30.
17. Ahn D, Sohn JH, Kim JH, Shin CM, Jeon JH, Park JY. Preoperative subclinical hypothyroidism in patients with papillary thyroid carcinoma. Am J Otolaryngol. 2013 Jul-Aug; 34(4): 312-9.
18. Burningham AR, Krishnan J, Davidson BJ, Ringel MD, Burman KD. Papillary and follicular variant of papillary carcinoma of the thyroid: initial presentation and response to therapy. Otolaryngol Head Neck Surg. 2005 Jun; 132(6): 840-4.
19. Southgate K, Creagh F, Teece M, Kingswood C, Rees Smith B. A receptor assay for the measurement of TSH receptor antibodies in unextracted serum. Clin Endocrinol (Oxf). 1984 May; 20(5): 539-48.
20. Laurberg P, Wallin G, Tallstedt L, Abraham-Nordling M, Lundell G, Torring O. TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol. 2008 Jan; 158(1): 69-75.
21. Smith BR, Bolton J, Young S, Collyer A, Weeden A, Bradbury J, et al. A new assay for thyrotropin receptor autoantibodies. Thyroid. 2004 Oct; 14(10): 830-5.
22. Filetti S, Belfiore A, Amir SM, Daniels GH, Ippolito O, Vigneri R, et al. The role of thyroid-stimulating antibodies of Graves' disease in differentiated thyroid cancer. N Engl J Med. 1988 Mar; 318(12): 753-9.
23. Yano Y, Shibuya H, Kitagawa W, Nagahama M, Sugino K, Ito K. Recent outcome of Graves' disease patients with papillary thyroid cancer. Eur J Endocrinol. 2007 Sep; 157(3): 325-9.
24. Katz SB, Garcia AJ, Niepomniszcze H. Development of Graves' disease nine years after total thyroidectomy due to follicular carcinoma of the thyroid. Thyroid. 1997 Dec; 7(6): 909-11.
25. Kimura H, Yamashita S, Namba H, Tominaga T, Tsuruta M, Yokoyama N, et al. Interleukin-1 inhibits human thyroid carcinoma cell growth. J Clin Endocrinol Metab. 1992 Aug; 75(2): 596-602.